You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Drug Price Trends for GNP CHILD ALLERGY


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GNP CHILD ALLERGY

Average Pharmacy Cost for GNP CHILD ALLERGY

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GNP CHILD ALLERGY 12.5 MG/5 ML 46122-0674-26 0.01642 ML 2025-01-22
GNP CHILD ALLERGY 12.5 MG/5 ML 46122-0674-26 0.01692 ML 2024-12-18
GNP CHILD ALLERGY 12.5 MG/5 ML 46122-0674-26 0.01650 ML 2024-11-20
GNP CHILD ALLERGY 12.5 MG/5 ML 46122-0674-26 0.01762 ML 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Allergy Immunotherapy and Related Markets

Introduction to Allergy Immunotherapy

Allergy immunotherapy, also known as allergy shots or desensitization therapy, is a long-term treatment that aims to reduce symptoms for people with allergic rhinitis, allergic asthma, or insect sting allergy. This market is experiencing significant growth due to increasing prevalence of allergic conditions and advancements in treatment options.

Global Market Size and Growth

The global allergy immunotherapy market is projected to grow substantially in the coming years. As of 2023, the market value stood at $1.70 billion and is anticipated to reach $4.02 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.3% from 2024 to 2032[1].

Key Drivers of Market Growth

Several factors are driving the growth of the allergy immunotherapy market:

Increasing Prevalence of Allergies

The rising prevalence of allergic rhinitis, allergic asthma, and other allergic conditions globally is a significant driver. For instance, nearly 1 in 3 U.S. adults and more than 1 in 4 U.S. children had a seasonal allergy, eczema, or food allergy in 2021[3].

Government Support and Investments

Increasing government support to develop and launch immunotherapy products for untapped allergic conditions, along with investments by key players in research and development, is bolstering market growth[1].

Rising Awareness

Growing awareness among patients about the proper management of allergies is another crucial factor. This awareness is particularly high in regions like North America and the Asia Pacific, where there is a strong focus on healthcare and allergy management[1].

Regional Market Analysis

North America

North America is expected to observe considerable growth due to the well-established healthcare infrastructure, high treatment rates, and increasing adoption of novel allergy immunotherapies. Continuous efforts by key companies to strengthen their position in the region also support market growth[1].

Asia Pacific

The Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period. Factors such as the rising burden of patients suffering from allergies, shifting focus of key players to expand their presence, and increasing awareness among the population are driving this growth[1].

Latin America and Middle East & Africa

These regions accounted for a comparatively less market share in 2023 but are expected to witness considerable growth. Government initiatives to promote the adoption of immunotherapy products and rising grants for manufacturing and launching these products are key contributors to this growth[1].

Market Segmentation

Subcutaneous Immunotherapy

The subcutaneous immunotherapy segment is expected to lead the market. This method involves regular injections of allergens to build tolerance and is widely used for treating various allergic conditions[1].

Related Markets: Epinephrine and Allergy Diagnostics

Epinephrine Market

The global epinephrine market, which is closely related to allergy management, was valued at $2.6 billion in 2022 and is projected to reach $4.4 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032. The increase in severe allergic reactions, such as anaphylaxis, and advancements in product formulations and delivery devices are driving this market[3].

Allergy Diagnostics and Therapeutics

The global allergy diagnostics and therapeutics market was estimated at $33.06 billion in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. The therapeutics segment, which includes immunotherapy, holds the largest revenue share due to its focus on treating allergic conditions. The diagnostic segment is expected to witness the fastest CAGR due to increasing demand for precise and early identification of allergic conditions[4].

Price Projections and Market Trends

Cost-Effectiveness and Accessibility

The cost-effectiveness of treatments like epinephrine and the increasing accessibility of diagnostic tools in developing countries are crucial for market growth. However, concerns regarding the availability and accessibility of these treatments, especially in rural or underserved areas, remain a challenge[3][4].

Innovations in Treatment

Advancements in product formulations and delivery devices, such as needle-free injection systems and user-friendly auto-injectors, are enhancing convenience, safety, and efficacy. These innovations are expected to stimulate market growth and encourage broader adoption among patients[3].

Challenges and Future Outlook

Risks and Benefits of Immunotherapy

Immunotherapy, such as Oral Immunotherapy (OIT) for food allergies, comes with risks, including the potential for severe allergic reactions like anaphylaxis. Decisions to undertake such treatments must be made through a shared decision-making process between patients and healthcare specialists, considering the risks and benefits involved[5].

Need for Further Research

There is a need for further research to improve patient-important outcomes such as quality of life and protection from accidental reactions. This includes studies on the long-term effects of immunotherapy and the development of treatments with better safety profiles[5].

Key Takeaways

  • The global allergy immunotherapy market is projected to grow from $1.70 billion in 2023 to $4.02 billion by 2032.
  • North America and the Asia Pacific are key regions driving market growth.
  • Subcutaneous immunotherapy is expected to lead the market.
  • Related markets such as epinephrine and allergy diagnostics are also experiencing significant growth.
  • Innovations in treatment and diagnostic tools are crucial for market expansion.
  • There is a need for further research to improve treatment outcomes and safety profiles.

FAQs

Q: What is the projected growth rate of the global allergy immunotherapy market? A: The global allergy immunotherapy market is expected to grow at a CAGR of 10.3% from 2024 to 2032[1].

Q: Which region is expected to grow at the highest CAGR in the allergy immunotherapy market? A: The Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period[1].

Q: What are the main drivers of the allergy immunotherapy market? A: Key drivers include increasing prevalence of allergies, government support, investments in R&D, and rising awareness among patients[1].

Q: How does the epinephrine market relate to the allergy immunotherapy market? A: The epinephrine market is closely related as it addresses severe allergic reactions, and its growth is influenced by similar factors such as increasing prevalence of allergies and advancements in treatment options[3].

Q: What are the risks associated with Oral Immunotherapy (OIT) for food allergies? A: OIT can lead to severe allergic reactions like anaphylaxis, especially during the initial phase of treatment. It requires careful supervision by healthcare specialists and informed consent from patients[5].

Sources

  1. Fortune Business Insights: Allergy Immunotherapy Market Size, Share | Global Report, 2032
  2. JAMA Network: Prevalence and Severity of Food Allergies Among US Adults
  3. Allied Market Research: Epinephrine Market Size, Share | Segments | Forecast - 2033
  4. Grand View Research: Allergy Diagnostics And Therapeutics Market Report, 2030
  5. ASCIA: Oral Immunotherapy (OIT) for Food Allergy

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.